Shenzhen Neptunus Bioengineering announced that it has filed an application for a US Phase II clinical trial of Polydatin Injection. Polydatin is a Class I innovative traditional Chinese that aides microcirculation of the blood and is expected to be tested as a treatment for myocardial ischemia, cerebral ischemia, shock and other cardiovascular diseases. More details.... Stock Symbol: (SHE: 000078) Share this with colleagues: // //